Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Minneapolis, MN
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Clinic 42 And International Travel Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Bronx, NY
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
New York, NY
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Local Institution
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Columbia, SC
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Local Institution
mi
from
Columbia, SC
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Austin, TX
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Central Texas Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Bellaire, TX
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
St. Hope Foundation
mi
from
Bellaire, TX
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Dallas, TX
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
North Texas Infectious Disease Consultants
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Fort Worth, TX
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Tarrant County Infectious Disease Associates
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Sacramento, CA
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Orlando, FL
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Indianapolis, IN
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Washingtondc, MD
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Local Institution
mi
from
Washingtondc, MD
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Buffalo, NY
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
University at Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Charlotte, NC
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Local Institution
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Philadelphia, PA
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Houston, TX
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Therapeutic Concepts, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated:  3/17/2016
mi
from
Ciudad De Buenos Aires,
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Local Institution
mi
from
Ciudad De Buenos Aires,
Click here to add this to my saved trials
Effects of IGF-I in HIV Metabolic Disease
Effects of Recombinant IGF-I in HIV Associated Metabolic Disease
Status: Enrolling
Updated:  3/22/2016
mi
from
Dallas, TX
Effects of IGF-I in HIV Metabolic Disease
Effects of Recombinant IGF-I in HIV Associated Metabolic Disease
Status: Enrolling
Updated: 3/22/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Status: Enrolling
Updated:  3/22/2016
mi
from
Boston, MA
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Status: Enrolling
Updated: 3/22/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults
A Novel Therapy for Glucose Intolerance in HIV Disease
Status: Enrolling
Updated:  3/22/2016
mi
from
Stony Brook, NY
Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults
A Novel Therapy for Glucose Intolerance in HIV Disease
Status: Enrolling
Updated: 3/22/2016
State University of New York/General Clinical Research Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Status: Enrolling
Updated:  3/23/2016
mi
from
Denver, CO
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Status: Enrolling
Updated: 3/23/2016
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects
Status: Enrolling
Updated:  3/24/2016
mi
from
Overland Park, KA
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects
Status: Enrolling
Updated: 3/24/2016
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Urban Health Study II
Finding, Testing and Treating High-Risk Probationers and Parolees With HIV
Status: Enrolling
Updated:  3/25/2016
mi
from
San Francisco, CA
Urban Health Study II
Finding, Testing and Treating High-Risk Probationers and Parolees With HIV
Status: Enrolling
Updated: 3/25/2016
RTI International Urban Health Program
mi
from
San Francisco, CA
Click here to add this to my saved trials
WHC+ (Women's Health CoOp PLUS)
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated:  3/25/2016
mi
from
Research Triangle Park, NC
WHC+ (Women's Health CoOp PLUS)
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated: 3/25/2016
RTI International - Headquarters
mi
from
Research Triangle Park, NC
Click here to add this to my saved trials
WHC+ (Women's Health CoOp PLUS)
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated:  3/25/2016
mi
from
Pretoria,
WHC+ (Women's Health CoOp PLUS)
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated: 3/25/2016
Wesley Community Centre
mi
from
Pretoria,
Click here to add this to my saved trials
HIV/AIDS, Severe Mental Illness and Homelessness
HIV/AIDS, Severe Mental Illness and Homelessness
Status: Enrolling
Updated:  3/30/2016
mi
from
Boston, MA
HIV/AIDS, Severe Mental Illness and Homelessness
HIV/AIDS, Severe Mental Illness and Homelessness
Status: Enrolling
Updated: 3/30/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated:  3/30/2016
mi
from
Boston, MA
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated:  3/30/2016
mi
from
Boston, MA
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated:  3/30/2016
mi
from
New York, NY
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Columbia P&S CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated:  3/30/2016
mi
from
New York, NY
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
New York Blood Center CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated:  3/30/2016
mi
from
Cleveland, OH
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Case Clinical Research Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated:  3/30/2016
mi
from
Philadelphia, PA
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Penn Prevention Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Status: Enrolling
Updated:  4/5/2016
mi
from
Providence, RI
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Status: Enrolling
Updated: 4/5/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Reducing High Risk Behavior in Treatment Court
Delivering HIV Risk Reduction Services in Treatment Court
Status: Enrolling
Updated:  4/6/2016
mi
from
Philadelphia, PA
Reducing High Risk Behavior in Treatment Court
Delivering HIV Risk Reduction Services in Treatment Court
Status: Enrolling
Updated: 4/6/2016
Philadelphia Treatment Court
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated:  4/7/2016
mi
from
Birmingham, AL
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated:  4/7/2016
mi
from
Baltimore, MD
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated:  4/7/2016
mi
from
Seattle, WA
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Applying the Use of Motivational Tools to Auditory Rehabilitation
Applying the Use of Motivational Tools to Auditory Rehabilitation
Status: Enrolling
Updated:  4/8/2016
mi
from
Portland, OR
Applying the Use of Motivational Tools to Auditory Rehabilitation
Applying the Use of Motivational Tools to Auditory Rehabilitation
Status: Enrolling
Updated: 4/8/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
San Francisco, CA
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Bridge HIV CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
New York, NY
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Columbia P&S CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
New York, NY
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
New York Blood Center CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
Philadelphia, PA
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Penn Prevention Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
Seattle, WA
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
Rochester, NY
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated:  4/12/2016
mi
from
Nashville, TN
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
Status: Enrolling
Updated:  4/19/2016
mi
from
Washington DC,
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
Status: Enrolling
Updated: 4/19/2016
Family and Medical Counseling Services
mi
from
Washington DC,
Click here to add this to my saved trials
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Status: Enrolling
Updated:  4/20/2016
mi
from
Boston, MA
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Status: Enrolling
Updated: 4/20/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated:  4/20/2016
mi
from
Birmingham, AL
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated: 4/20/2016
Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated:  4/20/2016
mi
from
Philadelphia, PA
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated: 4/20/2016
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy
A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV
Status: Enrolling
Updated:  5/3/2016
mi
from
Philadelphia, PA
Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy
A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV
Status: Enrolling
Updated: 5/3/2016
Division of Infectious Diseases & HIV Medicine at Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials